Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Neuroone Medical Technologies (NMTC) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for Neuroone Medical Technologies (NMTC) over the last 11 years, with Q4 2025 value amounting to 59.02%.

  • Neuroone Medical Technologies' EBITDA Margin fell 1112900.0% to 59.02% in Q4 2025 from the same period last year, while for Dec 2025 it was 87.71%, marking a year-over-year increase of 303100.0%. This contributed to the annual value of 46.46% for FY2025, which is 2978000.0% up from last year.
  • As of Q4 2025, Neuroone Medical Technologies' EBITDA Margin stood at 59.02%, which was down 1112900.0% from 50.02% recorded in Q3 2025.
  • Over the past 5 years, Neuroone Medical Technologies' EBITDA Margin peaked at 52.26% during Q4 2024, and registered a low of 13134.27% during Q1 2021.
  • For the 5-year period, Neuroone Medical Technologies' EBITDA Margin averaged around 2954.78%, with its median value being 653.59% (2023).
  • Per our database at Business Quant, Neuroone Medical Technologies' EBITDA Margin plummeted by -53255700bps in 2021 and then skyrocketed by 80590200bps in 2023.
  • Neuroone Medical Technologies' EBITDA Margin (Quarter) stood at 8324.42% in 2021, then soared by 81bps to 1557.31% in 2022, then soared by 78bps to 346.8% in 2023, then soared by 115bps to 52.26% in 2024, then crashed by -213bps to 59.02% in 2025.
  • Its EBITDA Margin stands at 59.02% for Q4 2025, versus 50.02% for Q3 2025 and 111.23% for Q2 2025.